Medulloblastoma
PA Northcott, GW Robinson, CP Kratz… - Nature reviews Disease …, 2019 - nature.com
Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological
variables pertaining to age, presence of metastases, extent of resection, histological …
variables pertaining to age, presence of metastases, extent of resection, histological …
Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)
PURPOSE SJMB03 (ClinicalTrials. gov identifier: NCT00085202) was a phase III risk-
adapted trial that aimed to determine the frequency and clinical significance of biological …
adapted trial that aimed to determine the frequency and clinical significance of biological …
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the
cerebellum, succumb to their disease. Conventional response monitoring by imaging and …
cerebellum, succumb to their disease. Conventional response monitoring by imaging and …
Children's oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma
JM Michalski, AJ Janss, LG Vezina, KS Smith… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Children with average-risk medulloblastoma (MB) experience survival rates of≥
80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects …
80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects …
[HTML][HTML] Improving radiotherapy in cancer treatment: Promises and challenges
HHW Chen, MT Kuo - Oncotarget, 2017 - ncbi.nlm.nih.gov
Effective radiotherapy for cancer has relied on the promise of maximally eradicating tumor
cells while minimally killing normal cells. Technological advancement has provided state-of …
cells while minimally killing normal cells. Technological advancement has provided state-of …
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
Background Patients with incomplete surgical resection of medulloblastoma are
controversially regarded as having a marker of high-risk disease, which leads to patients …
controversially regarded as having a marker of high-risk disease, which leads to patients …
Cytogenetic prognostication within medulloblastoma subgroups
Purpose Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group
3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical …
3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical …
Medulloblastoma: from myth to molecular
V Ramaswamy, MD Taylor - Journal of Clinical Oncology, 2017 - ascopubs.org
Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
We undertook a comprehensive clinical and biological investigation of serial
medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family …
medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family …